Clinical relevance of botulinum toxin immunogenicity (Q26824771)

main subject

Clostridium botulinum

1 reference

2 November 2019

botulinum toxin type A

1 reference

20 November 2019

Reiner Benecke

1

1 reference

language of work or name

1 reference

1 April 2012

5 references

28 September 2019

2 November 2019

20 November 2019

29 June 2022

5 references

28 September 2019

2 November 2019

20 November 2019

29 June 2022

26

1 reference

issue

2

1 reference

page(s)

e1-9

1 reference

Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Is it possible to accurately determine content of botulinum neurotoxin type A in drug products?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

EFNS guidelines on diagnosis and treatment of primary dystonias

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Xeomin: an innovative new botulinum toxin type A.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Antibodies against erythropoietin and other protein-based therapeutics: an overview

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Clinical presentation and management of antibody-induced failure of botulinum toxin therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Basic immunological aspects of botulinum toxin therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Molecular properties of a hemagglutinin purified from type A Clostridium botulinum

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Botulinum toxin therapy, immunologic resistance, and problems with available materials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Studies on the dissociation of botulinum neurotoxin type A complexes.

31 May 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Long-term botulinum toxin efficacy, safety, and immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Xeomin is free from complexing proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

A long-term follow-up of botulinum toxin A in cervical dystonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Clinical impact of antibody formation to botulinum toxin A in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

A radioimmuno-precipitation assay for antibodies to botulinum A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Consistent biochemical data are essential for comparability of botulinum toxin type A products

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599840-000000000-00000

Pharmacology of botulinum neurotoxin serotype A.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3683397

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences

28 November 2018

1 reference

12 December 2020

Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay

1 reference

12 December 2020

Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery

1 reference

12 December 2020

Development of resistance to botulinum toxin type A in patients with torticollis

1 reference

12 December 2020

On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin

1 reference

12 December 2020

Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study

1 reference

12 December 2020

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

1 reference

12 December 2020

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia

1 reference

12 December 2020

Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins

1 reference

12 December 2020

Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A--a preliminary observation

1 reference

12 December 2020

Botulinum toxin therapy for cervical dystonia

1 reference

12 December 2020

Serial neurophysiological studies of intramuscular botulinum-A toxin in humans

1 reference

12 December 2020

Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure

1 reference

12 December 2020

Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins

1 reference

12 December 2020

Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy

1 reference

12 December 2020

Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?

1 reference

12 December 2020

Mouse diaphragm assay for detection of antibodies against botulinum toxin type B

1 reference

12 December 2020

Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm

1 reference

12 December 2020

10.2165/11599840-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

0 references

1 reference

PubMed publication ID

22385408

1 reference